Molecular influences in thyroid and parathyroid surgery

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 15, Issue 2, 2001, Pages 177-188

  Mihai, Radu ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

CaR (calcium receptor); Genetic screening; MEN 1 syndrome; MEN 2 syndrome

Indexed keywords

CALCIUM CHANNEL STIMULATING AGENT; CALCIUM RECEPTOR; GADOLINIUM; LANTHANUM; MEMBRANE RECEPTOR; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; NEOMYCIN; NPD R 568; UNCLASSIFIED DRUG;

CANCER MODEL; CLINICAL RESEARCH; CLINICAL TRIAL; EARLY DIAGNOSIS; GENE; GENE TRANSFER; GENETIC SCREENING; HUMAN; HYPERPARATHYROIDISM; LABORATORY TEST; LYMPH NODE; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR CLONING; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; NEUROFIBROMATOSIS; NONHUMAN; ONCOGENE; PARATHYROID TUMOR; PARATHYROIDECTOMY; PATHOGENESIS; PHARMACOLOGICAL STIMULATION; POLYMERASE CHAIN REACTION; REVIEW; SIPPLE SYNDROME; SURGEON; TECHNIQUE; THYROID CARCINOMA; THYROID SURGERY; THYROID TUMOR; TUMOR CLASSIFICATION;

EID: 0034910278     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2001.0134     Document Type: Article

References (50)

1. Genetic aspects of adenomatosis of endocrine glands
2. The phospholipase C beta 3 gene located in the MEN-1 region shows loss of expression in endocrine tumours
3. Variable regions of chromosome II loss in different pathological tissues of a patient with MEN-1 syndrome
4. Positional cloning of the gene for multiple endocrine neoplasia-type 1
5. Identification of the multiple endocrine neoplasia type 1 (MEN-1) gene
6. Characterisation of mutations in patients with multiple endocrine neoplasia type 1
7. Predictive testing for multiple endocrine neoplasia type 1 using DNA polymorphism
8. Clonality of parathyroid tumours in familial MEN type 1
9. Somatic mutation of the MEN1 gene in parathyroid tumours
10. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism
11. Alterations of the MEN1 gene in sporadic parathyroid tumours
12. Multiple endocrine neoplasia type 2-associated RET protooncogene mutations do not contribute to the pathogenesis of sporadic parathyroid tumors
13. The association of phaeochromocytoma with carcinoma of the thyroid gland
14. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2
15. Mutations in the RET protooncogene are associated with MEN2A and FMTC
16. Germline mutations of the RET protooncogene in multiple endocrine neoplasia type 2A
17. RET mutations in human disease
18. Expression of the RET protooncogene in hyperparathyroid tissues: Implications for the pathogenesis of the parathyroid disease in MEN2A
19. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B
20. Genotype-phenotype correlation in MEN2: Report of the International RET Mutations Consortium
21. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma
22. No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 2B
23. Parent of origin effects in multiple endocrine neoplasia type 2B
24. RET activation by germline MEN-2A and MEN-2B mutations
25. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma
26. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2
27. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2
28. RET protooncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma
29. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations
30. Multiple endocrine syndrome type IIB in early childhood
31. Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity
32. RET mutations in exons 13 and 14 of FMTC patients
33. 2+-sensing receptor from bovine parathyroid
34. Mutations in the human calcium-sensing receptor gene cause familial hypocalciuric hypercalaemia and neonatal severe hyperparathyroidism
35. The extracellular calcium-sensing receptor gene in human parathyroid tumours
36. No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas
37. Genetic abnormalities in sporadic parathyroid adenomas: Loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus
38. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism
39. Decreased expression of calcium-sensing receptor messenger ribonucleic acid in parathyroid adenomas
40. 2+-sensing receptor expression in parathyroid adenoma
41. Complete cloning and sequencing of rat gp330/'megalin', a distinct member of the low density lipoprotein receptor gene family
42. Hyperparathyroidism is associated with reduced expression of a parathyroid calcium receptor mechanism defined by monoclonal antiparathyroid antibodies
43. 2+ receptor expressed in Xenopus laevis oocytes by NPS-467 R NPS-568
44. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism
45. Treatment of hypercalcaemia secondary to parathyroid carcinoma with a novel calcimimetic agent
46. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure
47. Thyrotropin receptor polymorphism and thyroid diseases
48. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes
49. Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma
50. Cloning and characterization of the thyroid iodide transporter